OTIS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
OTIS is not a good buy right now. The stock is still in a weakening short-term trend (MACD histogram negative and expanding), and the post-earnings tone is mixed (EPS beat but revenue miss). While it’s oversold (RSI_6 ~27) and near support that could trigger a bounce, there is no Intellectia buy signal today and the 1-month probabilistic trend is negative (-4.48%). For an impatient buyer, the risk/reward is not compelling enough to chase immediately in pre-market.
Price/levels: Pre-market 86.8, below the pivot 88.426 and sitting between S1 85.505 and pivot resistance; near-term overhead resistance at R1 91.348.
Momentum: MACD histogram -0.216 and negatively expanding = bearish momentum still strengthening.
RSI: RSI_6 ~27 (oversold/washed-out), which supports a potential short-term dead-cat bounce, but it’s not a confirmed trend reversal.
Moving averages: Converging MAs suggests transition/indecision, but with current negative momentum it favors continued chop-to-down until a reclaim of the pivot (88.4).
Pattern-based expectation: Similar-pattern model shows modest upside next week (+3.11%) but negative next month (-4.48%), reinforcing “bounce risk within a broader soft patch.”
Intellectia Proprietary Trading Signals
Q4 2025 growth and profitability improved: revenue +3.29% YoY, net income +10.98%, EPS +13.10%, gross margin up to 30.22% (+3.60% YoY).
Record adjusted free cash flow ($817M) and continued service/modernization growth (organic service +5%, modernization +9%) support quality/defensiveness.
Dividend declared ($0.42/share) supports shareholder-return narrative.
Flow/support: Hedge funds are buying (reported +676% QoQ buying amount).
Q4 revenue missed expectations and the stock sold off on the print (earnings headline pressure still present).
Technical momentum is still bearish (MACD negative and worsening), so the chart is not yet confirming a reversal.
Short-term options volume skews bearish (put-heavy trading), suggesting traders are still hedging/leaning down.
No recent insider buying signal (insiders neutral) and no congress trading data to validate influential accumulation.
Latest quarter: 2025/Q4. Top line: Revenue $3.796B, +3.29% YoY (steady but not explosive). Bottom line: Net income $374M, +10.98% YoY; EPS $0.95, +13.10% YoY (profit growth outpacing sales). Margins: Gross margin 30.22%, up ~3.60% YoY (favorable mix/efficiency). Overall: Fundamentals look healthy with improving profitability, but the market is currently focused on the revenue miss and near-term growth quality.
Recent trend (ratings/targets): Mixed, slightly negative on the margin due to recent target trims after the Q4 report.
